Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group obtained marketing approval for the Peceleganan Spray, according to a Tuesday Hong Kong bourse filing.
The drug was developed under an exclusive partnership by Chia Tai Tianqing Pharmaceutical.
The approval is for the treatment of wound infections secondary to first-degree or superficial second-degree burns and scalds caused by Staphylococcus epidermidis, Staphylococcus haemolyticus and Acinetobacter baumannii.